Modulation of tumor necrosis factor release from alveolar macrophages treated with pentamidine isethionate.
Alveolar macrophages in AIDS patients have a marked increase in tumor necrosis factor release in active Pneumocystis carinii pneumonia. We have demonstrated that pentamidine, an aromatic diamidine currently used to treat AIDS-related P. carinii pneumonia, is an effective inhibitor of cellular tumor necrosis factor release from lipopolysaccharide-stimulated rat alveolar macrophages at concentrations greater than 10(-8) M. Inhibition of release is not dependent upon the continued presence of pentamidine in the culture medium during the release phase. In addition, this blockage occurs at neither the transcriptional level as determined by Northern blot analysis nor the translational level as determined by Western blot analysis. Timed addition studies suggest that pentamidine is targeting relatively early events following lipopolysaccharide administration. Pentamidine appears to alter early lipopolysaccharide-induced cellular processes associated with the release of tumor necrosis factor from macrophages.
Corsini
E
E
Immunotoxicology Section, National Institute of Environmental Health Sciences, Research Triangle Park, NC 27709.
Craig
W A
WA
Rosenthal
G J
GJ
D000163:Acquired Immunodeficiency Syndrome / Q000276:immunology; D000818:Animals; D002478:Cells, Cultured; D005260:Female; D008070:Lipopolysaccharides; D016676:Macrophages, Alveolar / Q000187:drug effects / Q000378:metabolism*; D010419:Pentamidine / Q000494:pharmacology*; D014176:Protein Biosynthesis / Q000187:drug effects; D051381:Rats; D011916:Rats, Inbred F344; D014158:Transcription, Genetic / Q000187:drug effects; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis / Q000378:metabolism*
D008070:Lipopolysaccharides; D014409:Tumor Necrosis Factor-alpha; D010419:Pentamidine